MedTrace Logo

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

NCT02561234 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-08-06

No results posted yet for this study

Summary

A first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers.

Conditions

Interventions

DRUG

Co-ArgI-PEG

Administered IV

Sponsors & Collaborators

  • Aeglea Biotherapeutics (Study sponsor)

    collaborator UNKNOWN

  • Immedica Pharma AB

    lead INDUSTRY

Principal Investigators

  • Mattias Rudebeck, PhD MSc BMedSc · Immedica Pharma AB

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-22
Primary Completion
2019-05-28
Completion
2019-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02561234 on ClinicalTrials.gov